Gawlik A, Gieburowska J, Małecka-Tendera E. Cardiometabolic risk factors in Turner syndrome. Pediatric Endocrinology Diabetes and Metabolism. 2014;20(2).
APA
Gawlik, A., Gieburowska, J., & Małecka-Tendera, E. (2014). Cardiometabolic risk factors in Turner syndrome. Pediatric Endocrinology Diabetes and Metabolism, 20(2).
Chicago
Gawlik, Aneta, Joanna Gieburowska, and Ewa Małecka-Tendera. 2014. "Cardiometabolic risk factors in Turner syndrome". Pediatric Endocrinology Diabetes and Metabolism 20 (2).
Harvard
Gawlik, A., Gieburowska, J., and Małecka-Tendera, E. (2014). Cardiometabolic risk factors in Turner syndrome. Pediatric Endocrinology Diabetes and Metabolism, 20(2).
MLA
Gawlik, Aneta et al. "Cardiometabolic risk factors in Turner syndrome." Pediatric Endocrinology Diabetes and Metabolism, vol. 20, no. 2, 2014.
Vancouver
Gawlik A, Gieburowska J, Małecka-Tendera E. Cardiometabolic risk factors in Turner syndrome. Pediatric Endocrinology Diabetes and Metabolism. 2014;20(2).
Congenital cardiovascular structural abnormalities, hypertension, low birth weight, increased prevalence of obesity, frequent glucose intolerance and dyslipidemia are risk factors of premature mortality for cardiovascular events in Turner syndrome (TS). The life expectancy in TS is reduced by at least 10 years and the risk of premature death is increased 3-fold compared to general female population. Hormonal therapy in TS, both estrogens in different algorithms and growth hormone in supraphysiological dose, may additionally modify these factors. In this review we summarize cardiometabolic markers potentially present in girls and women with TS.
